Kura Oncology KURA Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -443.5%+6.4pp | -449.9%-73.0pp | -377%+13.0pp | -390%-16.8pp | -373.2%-14.6pp | |
| Net margin | -411.2%+1.8pp | -412.9%-72.0pp | -340.9%+9.1pp | -350%-16.4pp | -333.6%-10.7pp | |
| EBITDA margin | -441.9%+6.5pp | -448.4%-72.8pp | -375.7%+12.8pp | -388.4%-16.8pp | -371.6%-14.6pp | |
| Returns | ||||||
| Return on equity | -124.7%-29.9pp | -94.8%-29.7pp | -65.1%-14.0pp | -51.1%-9.3pp | -41.8%+1.1pp | |
| Return on assets | -42.2%-5.0pp | -37.2%+1.3pp | -38.4%-5.5pp | -32.9%-4.9pp | -28%+0.7pp | |
| Return on invested capital | -149.3%+92.4pp | -241.7%-156pp | -86%-21.5pp | -64.6%-14.5pp | -50%+16.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 6.1×+0.1× | 6.1×+0.9× | 5.1×-1.0× | 6.2×-1.9× | 8.1×-1.4× | |
| Quick ratio | 6.1×+0.1× | 6.1×+0.9× | 5.1×-1.0× | 6.2×-1.9× | 8.1×-1.4× | |
| Cash ratio | 0.4×-0.9× | 1.3×+0.5× | 0.8×0.0× | 0.8×+0.2× | 0.6×-2.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Interest coverage | -216.7×-15.9× | -200.8×-48.0× | -152.8×-14.5× | -138.4×-11.4× | -126.9×-7.6× | |
| Per Share | ||||||
| Book value per share | $1.22-38.7% | $1.99-28.2% | $2.77-20.7% | $3.49-16.3% | $4.17-13.2% | |
| Valuation | ||||||
| Market capitalization | $919.7M+81.6% | $904.11M+17.7% | $768.16M+48.4% | $517.72M-2.9% | $532.98M-21.3% | |
| Enterprise value | $904.89M+90.7% | $775.47M+12.0% | $692.33M+52.1% | $455.24M-9.1% | $501.07M+6.7% | |
| Price / sales | 12.8×+3.5× | 13.4×+1.3× | 12.1×+2.9× | 9.2×-0.6× | 9.8×-2.8× | |
| Price / book | 8.5×+7.1× | 5.2×+2.0× | 3.2×+1.5× | 1.7×+0.2× | 1.5×-0.2× | |
| EV / sales | 12.6×+3.9× | 11.5×+0.6× | 10.9×+2.8× | 8.1×-1.1× | 9.2×+0.5× | |
| Earnings yield | -32%+3.9pp | -30.8%-2.6pp | -28.2%+9.9pp | -38.1%-4.0pp | -34.1%-8.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Kura Oncology's ratios come from?
- Every ratio is computed from Kura Oncology's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
